An evaluation of efficacy and safety of Statin versus Bempedoic acid versus Bempedoic acid plus Ezetemibe in dyslipidemic North Indian population at tertiary care centre. - BEMPE

Start Date01 May 2025

Sponsor / Collaborator

Institute of Medical Sciences, Banaras Hindu University

NCT06925100

/ Not yet recruitingPhase 4

A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan - The CLEAR Taiwan Study

Cardiovascular disease (CVD) is a chronic non-communicable disease among the most common causes of death worldwide. Substantial reductions in risks of CVD can be achieved through the management of modifiable risk factors, particularly low-density lipoprotein cholesterol (LDL-C). However, only 18.3% of high-risk primary prevention patients and 20.7% of secondary prevention patients achieved the treatment goals based on the 2019 ESC guidelines. Similar trends were reported by the latest European multinational observational SANTORINI study. These real-world evidence data indicate the suboptimal implementation of ESC/EAS 2019 guidelines on LDL-C, particularly the low use of combinational lipid-lowering therapy (LLT), leading to a substantial proportion of patients remaining at high residual risk of ASCVD events.
Bempedoic acid, a first-in-class novel nonstatin lipid-lowering agent, was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2020 for the treatment of primary hypercholesterolemia. Bempedoic acid inhibits cholesterol biosynthesis through the inhibition of adenosine triphosphate-citrate lyase, an upstream enzyme of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The unique hepatic activation of bempedoic acid results in limited exposure to skeletal muscle, which prevents musculoskeletal-related adverse events.
Phase II and III RCTs have demonstrated efficacy with adequate safety data of bempedoic acid as mono- or combination therapy with statins and ezetimibe. The CLEAR outcomes trial demonstrated the benefit of bempedoic acid in lowering the risks of major adverse cardiovascular events in statin-intolerant patients.
However, there is limited data on bempedoic acid treatment in East Asian subjects and no data in the Taiwanese population, despite modeling data from large studies indicating the potential for no ethnic differences. To investigate the effectiveness and safety of bempedoic acid in a Taiwanese population, this phase IV study is conducted to examine the treatment outcomes in approximately 180 patients using bempedoic acid in Taiwan.

Start Date01 Apr 2025

Sponsor / Collaborator

Daiichi Sankyo Taiwan Ltd.

CTRI/2025/03/082077

/ Not yet recruitingNot ApplicableIIT

A study to compare the effect of Bempedoic acid added to statin therapy vs statin monotherapy in lowering the remnant cholesterol in established Atherosclerotic cardiovascular disease(ASCVD) patients: A randomized controlled trial - nil

Start Date15 Mar 2025

Sponsor / Collaborator-

100 Clinical Results associated with Bempedoic acid

100 Translational Medicine associated with Bempedoic acid

100 Patents (Medical) associated with Bempedoic acid

507

Literatures (Medical) associated with Bempedoic acid

01 Dec 2025·Current Atherosclerosis Reports

Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk

Review

Author: Kalaitzidis, Rigas G ; Vlachakis, Panayotis K ; Theofilis, Panagiotis ; Karakasis, Paschalis

PURPOSE OF REVIEW:

The review aims to address the complex relationship between dyslipidemia and chronic kidney disease (CKD), emphasizing its dual role in driving cardiovascular disease (CVD) risk and contributing to CKD progression. It explores pathophysiological mechanisms, highlights recent biomarker discoveries, and evaluates contemporary and emerging lipid-lowering therapies tailored for CKD patients.

RECENT FINDINGS:

Recent studies have highlighted the inadequacy of traditional lipid markers like LDL-C in reflecting cardiovascular risk in CKD. Novel biomarkers, such as remnant cholesterol and lipoprotein(a), demonstrate stronger associations with adverse outcomes. Emerging lipid-lowering agents, including bempedoic acid, pemafibrate, and PCSK9 inhibitors, show promise for risk reduction, especially in non-dialysis-dependent CKD. However, evidence remains limited for advanced stages of CKD and dialysis patients. Furthermore, alterations in lipid metabolism, such as dysfunctional HDL and triglyceride-rich lipoproteins, are now recognized as significant contributors to CVD and renal damage in CKD populations. Dyslipidemia is a pivotal modifiable risk factor in CKD, exacerbating both cardiovascular risk and disease progression. While statins remain the cornerstone of therapy in early-to-moderate CKD, their efficacy diminishes in advanced stages. The advent of novel therapeutic options and a deeper understanding of dyslipidemia's pathophysiology hold potential for improving outcomes. Future research should prioritize personalized approaches, focusing on the unique metabolic derangements of CKD and advancing treatments for high-risk and dialysis-dependent patients.

01 Jun 2025·DRUGS

Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions

Review

Author: Commodari, Daniela ; D'Erasmo, Laura ; Arca, Marcello ; Arizaj, Ina ; Carosi, Martina ; Minicocci, Ilenia ; Castellese, Jacopo ; Tramontano, Daniele ; Sansone, Giorgia ; Maiorca, Carlo ; Bini, Simone ; Di Costanzo, Alessia ; Covino, Stella

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Quantitative and qualitative changes in plasma lipoprotein profiles are frequently associated with CKD and represent a significant risk factor for CVD in patients with CKD. Guidelines from the European Society of Cardiology and the European Atherosclerosis Society classify CKD as a condition with high or very high cardiovascular risk and set specific low-density lipoprotein cholesterol targets. Conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and fibrates, can control CKD-associated dyslipidemia and, to some extent, prevent major atherosclerotic events in patients with CKD, but their use in clinical practice presents challenges because of the potential renal safety concerns. In recent years, novel therapies with the ability to lower both low-density lipoprotein cholesterol and triglycerides have been introduced to the market (e.g., proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, lomitapide, volanesorsen) to improve our ability to control lipid abnormalities. However, their impact on kidney functionality has not been fully elucidated. The aim of this review was to examine the renal safety profiles of various LLTs, with special reference to novel medications, and to highlight important considerations and guidance for the use of these medications in overt CKD or in patients with some degree of renal function impairment. We underscore the lack of a comprehensive understanding of kidney safety, particularly for novel LLT therapies, and strongly emphasize the importance of future dedicated research to fully assess the safety and efficacy of these agents in patients with kidney abnormalities.

01 Jun 2025·HOSPITAL PHARMACY

Lipid-Lowering Therapy Associated Erectile Dysfunction and Testicular Pain: A Rare Case Report

Article

Author: Dharwadkhar, Sachin ; Mahadevappa, Manjappa ; Madapat, Kevin Jose ; Hussain, Sakeer

Lipid-lowering therapy (LLT) includes a diverse group of pharmaceuticals designed to reduce blood levels of cholesterol and triglyceride (TG), helping to prevent cardiovascular diseases like myocardial infarction and stroke. LLT includes treatment with several lipid-lowering drugs (LLD), including hydroxymethylglutaryl (HMG-CoA) reductase inhibitors (statin), PCSK9 Inhibitors, cholesterol-absorbing inhibitors (Ezetimibe), Bile Acid Sequestrants, Fibrates, Niacin (Vitamin B3), Omega-3 Fatty Acids, Bempedoic Acid, and combination therapy. The efficacy and safety of these molecules vary widely. Statins are the first-line LLD for treating hypercholesterolemia and are widely used for cardiovascular disease prevention. Common side effects include muscle-related issues such as myalgia, muscle atrophy, and, rarely, rhabdomyolysis. However, adverse effects on male reproductive health are infrequent and often underreported. Other medication classes employed in LLT mostly share many of the ADRs seen with statins, although individual classes may have unique ADRs depending on the pharmacokinetics and pharmacodynamics. Here, we are reporting a unique case of a 50-year-old male patient with no prior history of sexual dysfunction or testicular issues and other comorbidities or habits, who developed loss of libido, erectile dysfunction (ED) and testicular pain with most of the LLD, which promptly resolved on discontinuation of the LLT. This case highlights the importance of considering potential reproductive side effects when prescribing LLT and monitoring male patients for symptoms of sexual dysfunction.

News (Medical) associated with Bempedoic acid

12 May 2025

·www.esperion.com

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited (along with an affiliate); Dr. Reddy’s Laboratories Inc. (along with an affiliate); Hetero USA Inc. (along with affiliates); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding pending patent litigation and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. Esperion Contact Information: Investors: Alina Venezia investorrelations@esperion.com (734) 887-3903 Media: Tiffany Aldrich corporateteam@esperion.com (616) 443-8438

Patent Infringement

09 May 2025

·www.pharmaceutical-technology.com

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines

In 2024, the medicines’ indications were expanded to include cardiovascular risk minimisation in individuals who are not to take recommended statin therapy. Credit: chayanuphol / Shutterstock. HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Canada. HLS’s agreement with Esperion includes an upfront payment of $1m, another $1m upon Health Canada’s approval, customary royalties on future sales, and potential milestone payments related to pricing, reimbursement, and significant commercial sale goals. In addition, Esperion will obtain an upfront payment and be qualified for milestone payments of up to nearly $5m alongside tiered royalties on product sales. HLS plans to fund all upfront and milestone-based payments, as well as related launch expenses, via current cash reserves, negating the need for additional financing. The company also plans to utilise its existing commercial infrastructure, expecting no significant increase in operating costs. HLS is tasked with receiving approval for these medicines from Health Canada, which is anticipated by the end of this year. These medications are currently available in various European nations and the US. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The US Food and Drug Administration (FDA) initially approved the medicines in 2020 for cutting low-density lipoprotein cholesterol (LDL-C) levels. In 2024, their indications were expanded to include cardiovascular risk minimisation in individuals who are not to take recommended statin therapy. This decision was supported by data from the CLEAR Outcomes trial. In fourth quarter (Q4) of 2024, Esperion made new drug submissions to Health Canada for both medicines. The brand names for these drugs in Canada will be confirmed upon approval from the country’s regulator. HLS noted that more than half a million individuals in Canada could potentially benefit from these treatments, particularly those with elevated levels of LDL-C and those who are either statin intolerant or not meeting LDL-C goals in spite of statins and ezetimibe combination therapy. HLS Therapeutics CEO Craig Millian said: “We look forward to working with Esperion to bring these innovative treatments to the many Canadians suffering from, or at risk of, cardiovascular disease.”

Drug ApprovalLicense out/in

08 May 2025

·www.esperion.com

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to commercialize NEXLETOL* and NEXLIZET* in Canada. Under the terms of the agreement, Esperion will receive an upfront payment, near-term milestone and tiered royalties on product sales. Esperion will be responsible for supplying finished product to HLS Therapeutics at a profitable transfer price. According to the Government of Canada, approximately one in 12 Canadian adults aged 20 and over, which represents 2.6 million people, are living with diagnosed heart disease. It is the second leading cause of death in Canada, with approximately 14 Canadian adults aged 20 and over dying every hour due to diagnosed heart disease. “We are excited about the opportunity to partner with Esperion to bring these innovative treatments to the many Canadians suffering from, or at risk of, cardiovascular disease,” said Craig Millian, CEO at HLS. “We’re thrilled to collaborate with HLS to expand the reach of our therapies to patients throughout Canada who are at risk of cardiovascular disease,” said Sheldon Koenig, President and CEO of Esperion. “This collaboration underscores and supports our commitment to expand global access to our potentially life-saving therapies.” Details of the Agreement and Financial Terms Under the terms of the license and distribution agreement, Esperion will grant HLS Therapeutics exclusive commercialization rights to NEXLETOL and NEXLIZET in Canada. HLS Therapeutics will be responsible for commercialization, including reimbursement and marketing. Esperion will receive an upfront payment and be eligible for milestone payments of up to approximately $5 million along with tiered royalties on product sales. *NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) are the commercial brand names in the U.S. The brand names in Canada to be confirmed upon approval by Health Canada. About HLS Therapeutics Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS’s focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS’s management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. Esperion Contact Information: Investors: Alina Venezia investorrelations@esperion.com (734) 887-3903 Media: Tiffany Aldrich corporateteam@esperion.com (616) 443-8438

License out/inDrug Approval

100 Deals associated with Bempedoic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D10691	Bempedoic acid	C10AX15	DB11936

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	United States	Esperion Therapeutics, Inc.	22 Mar 2024
Myocardial Infarction	United States	Esperion Therapeutics, Inc.	22 Mar 2024
Primary Hyperlipidemia	United States	Esperion Therapeutics, Inc.	22 Mar 2024
Dyslipidemias	European Union	Daiichi Sankyo Europe GmbH	01 Apr 2020
Dyslipidemias	Iceland	Daiichi Sankyo Europe GmbH	01 Apr 2020
Dyslipidemias	Liechtenstein	Daiichi Sankyo Europe GmbH	01 Apr 2020
Dyslipidemias	Norway	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	European Union	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	Iceland	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	Liechtenstein	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	Norway	Daiichi Sankyo Europe GmbH	01 Apr 2020
Atherosclerosis	United States	Esperion Therapeutics, Inc.	21 Feb 2020
Heterozygous familial hypercholesterolemia	United States	Esperion Therapeutics, Inc.	21 Feb 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypercholesterolemia	NDA/BLA	Japan	Otsuka Pharmaceutical Co., Ltd.	26 Nov 2024
Hyper LDL cholesterolaemia	Phase 3	Japan	Otsuka Pharmaceutical Co., Ltd.	13 Feb 2023
Hyperlipidemias	Phase 3	United States	Esperion Therapeutics, Inc.	23 Oct 2017
Cerebrovascular Disorders	Phase 3	United States	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Argentina	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Australia	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Austria	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Belgium	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Brazil	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Bulgaria	Esperion Therapeutics, Inc.	22 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05683340 (CTgov)	Phase 3	Hyper LDL cholesterolaemia	96	Placebo	rffnfpmccz(icilkcbefl) = jjlhbfjlds pesstvhklv (ebmojwsqvv, 1.901) View more	-	13 Mar 2025
NCT02993406 (CLEAR Outcomes, Pubmed \| J Am Heart Assoc)	Phase 3	Obesity	6,177	Bempedoic Acid 180 mg	gqffrilmmh(nmrshfrsdn) = yittjaakfs iqrpmjnjik (mwpcfmuqqj, 0.76 [0.63 - 0.92]) View more	Positive	18 Feb 2025
				Placebo	-
ESC2024	Not Applicable	Cardiovascular Diseases	-	Bempedoic acid 180 mg daily	ziwlxosnol(ermirbmxle): OR = 0.84 (95% CI, 0.76 - 0.96)	Positive	30 Aug 2024
				Placebo
ENDO2024	Not Applicable	Diabetes Mellitus, Type 2 \| Hypercholesterolemia	7,475	Bempedoic acid	aurxxumpac(ymrdagekbn) = jscogfwgas qksvwzmihg (uemhjbxwek, -37.56 to -22.82) View more	Positive	01 Jun 2024
NCT05683340 (Company_Website) Manual	Phase 3	Hypercholesterolemia	96	Bempedoic acid 180 mg	pxtuwhujua(ucxmhufjdh) = sffuzqlocr cwdgezlelq (ydaxwgnhmq ) Met	Positive	20 May 2024
				Placebo	pxtuwhujua(ucxmhufjdh) = noaenawroo cwdgezlelq (ydaxwgnhmq ) Met
NCT04784442 (CTgov)	Phase 2	Hypercholesterolemia	188	Placebo	cmxcxtazlh(qxwqdkrlin) = hydecfdkin dabonimima (uxjmmkabue, 2.117) View more	-	04 Mar 2024
NCT02993406 (CLEAR Outcomes, CTgov)	Phase 3	Cardiovascular Diseases \| Coronary Artery Disease \| Cerebrovascular Disorders ... View more	13,970	Bempedoic acid 180 mg tablet (Bempedoic Acid 180 mg)	btyvoogfgz = huphekekxr sddcplpvuz (hwnfondbwu, akfdzsttks - cnjjkkfcpv) View more	-	03 Jan 2024
				Matching placebo tablet (Placebo Comparator)	btyvoogfgz = mzzpgfbbes sddcplpvuz (hwnfondbwu, lezwpwmrhn - rcdnlynjfa) View more
NCT02993406 (CLEAR Outcomes, ENDO2023)	Phase 3	Cardiovascular Diseases \| Coronary Artery Disease \| Cerebrovascular Disorders ... View more	-	Bempedoic Acid	dkvvyubqtr(vxrqajqdeo) = mmfqfsbajl kdqkaloyzn (khdgltkzba )	Positive	05 Oct 2023
MILOS (ESC2023)	Not Applicable	-	992	Bempedoic acid	punthzzwfz(vlvvyynzzy) = kjtkqgvsyc bfqaqgqxrl (bdkwqtyhbm, (84.1)) View more	-	26 Aug 2023
				Bempedoic acid + ezetimibe	punthzzwfz(vlvvyynzzy) = gvnwhibymc bfqaqgqxrl (bdkwqtyhbm, (123.6)) View more
NCT02993406 (Pubmed \| JAMA)	Phase 3	-	4,206	Bempedoic Acid	lenikiwguf(hqoanixpdm): HR = 0.61 (95% CI, 0.39 - 0.98) View more	Positive	24 Jun 2023
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bempedoic acid

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation